Возможность использования интерлейкина-2 при лечении остеосаркомы у собак.

Версия для печати

-2

.. (-)
.. "" (-)

® (-2) . , , . ® 10 000 / , .

.

. [3] , , , , . , [3, 14], 80 % [9] , -, ( ), [14].

- . ( ) , . ( ) .

, . -2 (®, "", -, , "").

, . 100-1000 . , . , - , , , , . , , , , . , , [5].

, , : -, (NK-), , - (LAK-), , - . , : -2, , γ-, -6, -4.

-2 . In vivo -2 -, CD25, - , NK- γ-, - , , - -2, , -1, -1, -6, -8, , - , - . [8].

, -2 (®) , : [4], [4], , [1], [7]. , [8] [2].

, , IL-2 [12]. ® , .

, , , . - , . (, , ) .

® 10000 / , . , , , .

, (. 1).

1. ® .

30
\ \
4,7± 0,2 19±2 5,2±0,3 15,4±1,3 11,0±1,5 4,2±0,3 21,0±2,3 5,5±0,4 14,9±1,8 13,0±1,5
4,7± 0,2 19±2 5,2±0,3 15,4±1,3 11,0±1,5 2,9±0,2* 12,0±0,1* 6,1±0,4 12,1±0,9 19,7±1,8
1,8± 0,3 4,5±0,3 6,5±0,7 7,2±0,5 27±2 1,8± 0,3 4,5±0,3 6,5±0,7 7,2±0,5 27±2

: \ - ; - ; - - , - ; - . * - <0,01

1, ® . 30 , (.1).

.

, : , ; : , .

®, 0.1 / , . .

. .
® .

Summary

Opportunity of medication Roncoleukin (interleukin-2) application was studied in treatment of oncological diseases of osteosarcoma in dogs. In the research it was demonstrated that during sarcoma development in dogs increase of sialic acids is observed as well as changes of some other blood indices. Intravenous infusion of Roncoleukin to sick animals in the dose 10000 units per kilogram together with addition of medication Biocephyt to food ration resulted in suspense of the cancerous growth and partial recovery of blood indices.

 

1. .. -2 (-2) . / .. , .. , .. , .. , .. , .. , .. . // . - 1995. - 154, 2. - . 57-60.
2. .. "-2/" ( 10 ). / .. , .. , .. , .. . // . - 1998. - 9. - . 3,6-7.
3. .. . / .. , .. // . - 1999. - 1(7). - . 16-19.
4. .. -2 (®) . / .. , .. , .. , .. // III . , 1999. .
5. A.M. ® . / A.M. , .. , .. , .. // . - 1999. - 1, 3-4. - . 129-130.
6. .. . / .. , .. , .. // . . " - 2000". , 2000. . . "® - -2 . ". - . 8-11.
7. .. . / .. // V " ". , 1999. . - . 440-449.
8. ..: -2 - . / .. , .. , .. , .. , .. , .. , .. , .. // / . - 1997. - 1, 1. - . 147.
9. Bach-Nelson S. The use of doubling time in veterinary clinical oncology. / S. Bach-Nelson, J.S. Reif, R.S. Brodey // Journal of the American Veterinary Radiological Society. - 1976. - V.17. - P. 113-116.
10. Jeal W. Aldesleukin (Recombinant Interleukin-2). / W. Jeal, K.L. Goa // Bio Drugs. - 1997. - V. 7(4). - P. 285-317.
11. Khanna C. Interleukin-2 liposome inhalation therapy is safe and effective for dogs with spontaneous pulmonary metastases. / C. Khanna, P.M. Anderson, D.E. Hasz, E. Katsanis, M. Neville, J.S. Klausner // Cancer. - 1997. - V. 79, N 7. - P. 1409-21.
12. Mariani E. Lytic activity of IL-2 and IL-12 stimulated NK cells against HOS osteosarcoma cell line. / E. Mariani, A. Tarozzi, A. Meneghetti, M. Tadolini, A. Facchini // Boll Soc Ital Biol Sper. - 1996. - V. 72, N 1-2. - P. 21-7.
13. Ohnishi H. Successful in vivo generation of canine lymphokine-aktivated killer cells by continuous recombinant interleukin-2 infusion through the splenic artery. / H Ohnishi, K. Okuno, M. Yasutomi. // Cancer Biother. - 1993. - V. 8, N 3. - P. 213-22.
14. Stevenson S. Fracture associated sarcomas. / S. Stevenson // Veterinary clinics of North America. - 1991. - V.21. - P. 859-872.


Версия для печати